MAP2K7 and glioblastoma: Taken together, our findings identify clinically important subgroups of NF1-mutant, IDH wild-type glioblastomas and delineate mechanisms of MEK inhibitor response, informing the development of synergistic therapies for NF1-mutant glioblastomas.